pancreatic cancer treatment

Pancreatic ductal adenocarcinoma remains one of the most difficult cancers to treat, with limited progress in drug development over the past decade. At the 2026 ASCO Annual Meeting, the Phase 3 RASolute 302 trial delivered results that stood out against…

In the quieter corners of European health policy, where attention is often fragmented and political capital fiercely contested, pancreatic cancer has long remained an uncomfortable outlier—aggressive, difficult to detect, and historically underprioritised. Yet, as Europe confronts an evolving cancer burden,…